Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$22.82 -1.2%	$20.56	$17.24 ▼ $28.56	$14.63B	0.96	1.17 million shs	1.11 million shs
NUVL Nuvalent	$78.24 +0.4%	$72.76	$55.54 ▼ $113.51	$5.62B	1.34	492,596 shs	364,260 shs
SMMT Summit Therapeutics	$19.78 -1.9%	$23.68	$6.78 ▼ $36.91	$14.69B	-1.06	3.65 million shs	2.89 million shs
TEVA Teva Pharmaceutical Industries	$17.00 -4.0%	$16.04	$12.47 ▼ $22.80	$19.49B	0.6	10.19 million shs	13.36 million shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	0.00%	+2.79%	+16.13%	+11.26%	-14.76%
NUVL Nuvalent	0.00%	+0.28%	+10.20%	+1.60%	-2.23%
SMMT Summit Therapeutics	0.00%	-3.93%	-14.34%	-4.86%	+139.76%
TEVA Teva Pharmaceutical Industries	0.00%	-4.30%	+0.99%	+3.80%	-1.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.7252 of 5 stars	3.3	5.0	0.0	1.9	0.0	3.1
NUVL Nuvalent	2.1636 of 5 stars	3.5	2.0	0.0	1.6	3.3	0.0
SMMT Summit Therapeutics	3.047 of 5 stars	4.4	3.0	0.0	2.5	1.7	0.0
TEVA Teva Pharmaceutical Industries	3.9833 of 5 stars	4.6	5.0	0.8	2.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.69	Moderate Buy	$39.17	71.63% Upside
NUVL Nuvalent	2.90	Moderate Buy	$115.50	47.62% Upside
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	77.41% Upside
TEVA Teva Pharmaceutical Industries	3.20	Buy	$24.44	43.82% Upside

Current Analyst Ratings Breakdown

Latest NUVL, TEVA, SMMT, and GMAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TEVA Teva Pharmaceutical Industries	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$21.00 ➝ $23.00
5/8/2025	SMMT Summit Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	TEVA Teva Pharmaceutical Industries	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
5/2/2025	SMMT Summit Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$37.00 ➝ $41.00
4/28/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.70	$1.54 per share	14.80	$8.04 per share	2.84
NUVL Nuvalent	N/A	N/A	N/A	N/A	$10.94 per share	N/A
SMMT Summit Therapeutics	$700K	20,985.62	N/A	N/A	$0.11 per share	179.82
TEVA Teva Pharmaceutical Industries	$16.62B	1.17	$3.37 per share	5.05	$4.75 per share	3.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.76	13.11	12.82	2.65	36.30%	16.78%	13.79%	8/14/2025 (Estimated)
NUVL Nuvalent	-$126.22M	-$4.39	N/A	N/A	N/A	N/A	-28.63%	-27.15%	8/14/2025 (Estimated)
SMMT Summit Therapeutics	-$614.93M	-$0.34	N/A	N/A	N/A	N/A	-85.42%	-52.66%	8/5/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$1.15	N/A	6.46	1.44	-9.91%	42.46%	6.65%	7/30/2025 (Estimated)

Latest NUVL, TEVA, SMMT, and GMAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	GMAB Genmab A/S	$0.23	$0.31	+$0.08	$0.31	$5.17 billion	$715.00 million
5/8/2025	Q1 2025	NUVL Nuvalent	-$1.14	-$1.18	-$0.04	-$1.18	N/A	N/A
5/7/2025	Q1 2025	TEVA Teva Pharmaceutical Industries	$0.47	$0.52	+$0.05	$0.18	$3.99 billion	$3.89 billion
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TEVA Teva Pharmaceutical Industries	$1.01	5.95%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	5.25	5.24
NUVL Nuvalent	N/A	23.07	23.07
SMMT Summit Therapeutics	N/A	8.31	8.31
TEVA Teva Pharmaceutical Industries	2.97	0.98	0.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
NUVL Nuvalent	97.26%
SMMT Summit Therapeutics	4.61%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
NUVL Nuvalent	10.20%
SMMT Summit Therapeutics	84.90%
TEVA Teva Pharmaceutical Industries	0.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	1,660	641.22 million	651.58 million	Optionable
NUVL Nuvalent	40	71.81 million	62.16 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	86.28 million	Optionable
TEVA Teva Pharmaceutical Industries	36,800	1.15 billion	1.13 billion	Optionable

NUVL, TEVA, SMMT, and GMAB Headlines

Recent News About These Companies

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $24.44 Average Price Target from Brokerages

June 15 at 2:23 AM | americanbankingnews.com

Hennessy Advisors Inc. Sells 74,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 14 at 7:42 AM | marketbeat.com

SG Americas Securities LLC Has $5.19 Million Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 13 at 4:22 AM | marketbeat.com

Americares, HDA honor Teva with Power of Partnership Award

June 12 at 12:05 PM | drugstorenews.com

Greenwood Capital Associates LLC Boosts Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 12 at 7:33 AM | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives Consensus Rating of "Buy" from Analysts

June 12 at 4:19 AM | marketbeat.com

Teva’s Next-Gen Trail Running Sandal Is Not Only Lighter — It’s Cheaper Too

June 11, 2025 | msn.com

Duquesne Family Office LLC Buys 5,882,350 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 11, 2025 | marketbeat.com

Assenagon Asset Management S.A. Has $91.97 Million Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

June 11, 2025 | marketbeat.com

Teva Honored With Power of Partnership Award for Global Health Impact

June 10, 2025 | finance.yahoo.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 10, 2025 | seekingalpha.com

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

June 10, 2025 | finance.yahoo.com

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

June 9, 2025 | zacks.com

The Goldman Sachs Group Begins Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

June 8, 2025 | americanbankingnews.com

Goldman Sachs Initiates Coverage of Teva Pharmaceutical Industries Limited - Depositary Receipt () (TEVA) with Buy Recommendation

June 7, 2025 | msn.com

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?

June 7, 2025 | benzinga.com

Traders Purchase High Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

June 6, 2025 | marketbeat.com

The Goldman Sachs Group Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA)

June 6, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (NYSE:TEVA) EVP Sells $105,626.12 in Stock

June 6, 2025 | insidertrades.com

Matthew Shields Sells 6,206 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock

June 5, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Presents at Jefferies Global Healthcare Conference Transcript

June 5, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUVL, TEVA, SMMT, and GMAB Company Descriptions

Genmab A/S NASDAQ:GMAB

$22.82 -0.27 (-1.17%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$22.81 -0.01 (-0.04%)

As of 06/13/2025 06:58 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Nuvalent NASDAQ:NUVL

$78.24 +0.33 (+0.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$78.28 +0.04 (+0.04%)

As of 06/13/2025 07:17 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Summit Therapeutics NASDAQ:SMMT

$19.78 -0.38 (-1.88%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.76 -0.03 (-0.13%)

As of 06/13/2025 07:59 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries NYSE:TEVA

$17.00 -0.71 (-4.03%)

Closing price 06/13/2025 03:59 PM Eastern

Extended Trading

$17.07 +0.07 (+0.40%)

As of 06/13/2025 07:57 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time